BRAF and Marinesco-Sjogren syndrome: Interestingly, a recent phase 2 study [120] evaluated the combination of encorafenib (BRAF inhibitor), cetuximab (anti-Endothelial Growth Factor Receptor (EGFR) monoclonal antibody), and nivolumab in patients with MSS, BRAF-V600E-mutated mCRC, a mutation frequently associated with CMS1 subgroup.